Elutia Inc. (ELUT)
NASDAQ: ELUT · IEX Real-Time Price · USD
2.850
+0.080 (2.89%)
At close: May 1, 2024, 3:49 PM
2.760
-0.090 (-3.16%)
After-hours: May 1, 2024, 4:00 PM EDT
Elutia Revenue
In the year 2023, Elutia had annual revenue of $24.75M with 3.76% growth. Revenue in the quarter ending December 31, 2023 was $5.88M, a -10.81% decrease year-over-year.
Revenue (ttm)
$24.75M
Revenue Growth
+3.76%
P/S Ratio
3.75
Revenue / Employee
$458,241
Employees
54
Market Cap
92.79M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
| Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
| Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
| Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
| Dec 31, 2019 | 42.90M | 3.86M | 9.90% |
| Dec 31, 2018 | 39.04M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SHL Telemedicine | 57.08M |
| Eton Pharmaceuticals | 32.64M |
| HOOKIPA Pharma | 20.13M |
| Myomo | 19.24M |
| Armata Pharmaceuticals | 4.53M |
| Abeona Therapeutics | 3.50M |
ELUT News
- 7 days ago - Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1 - GlobeNewsWire
- 7 weeks ago - Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024 - GlobeNewsWire
- 2 months ago - Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024 - GlobeNewsWire
- 4 months ago - Elutia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 6 months ago - Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results - GlobeNewsWire
- 6 months ago - Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million - GlobeNewsWire
- 6 months ago - Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 - GlobeNewsWire
- 8 months ago - Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference - GlobeNewsWire